The 1 December 2014 issue of the Schedule of Pharmaceutical Benefits is out and now in effect. The new Schedule includes the following new entries:

• Brentuximab vedotin (Adcetris) - new listing
• Enzalutamide (Xtandi) - new listing
• Escitalopram oxalate (Lexapro) - new formulation
• Eculizumab (Soliris) - new indication
• Fluticasone furoate with vilanterol trifenatate (Breo Ellipta) - new combination product
• Glycine with carbohydrate (Glycine500) - new combination product
• High fat formula wiyth vitamins, minerals and trace elements and low in protein and carbohydrate (Ketocal 4:1 LQ) - new formulation
• Infliximab (Remicade) - new indication
• Ivacaftor (Kalydeco) - new listing
• Rituximab (MabThera) - new indication
• Simeprevir sodium (Olysio) - new listing
• Triglycerides - long chain with glucose (SnoPro) - new formulation
• Umeclidinium bromide (Incruse Ellipta) - new listing 
• Vilanterol trifenatate with umeclidinium bromide (Anoro Ellipta) - new combination product
• Voriconazole (Vfend) - new indication

Their entries in MAESTrO have been updated.

For more details, go to: http://www.pbs.gov.au/browse/changes